Cargando…

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis

In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (Fluarix™) (ClinicalTrials.gov, NCT00753272). Participants received one dose of AS03-TIV or TIV in each study year and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Palacios, Guillermo M., Leroux-Roels, Geert, Beran, Jiri, Devaster, Jeanne-Marie, Esen, Meral, Launay, Odile, McElhaney, Janet E., van Essen, Gerrit A., Benoit, Anne, Claeys, Carine, Dewé, Walthère, Durand, Christelle, Duval, Xavier, Falsey, Ann R., Feldman, Gregory, Galtier, Florence, Gervais, Pierre, Hwang, Shinn-Jang, McNeil, Shelly, Richardus, Jan Hendrik, Trofa, Andrew, Oostvogels, Lidia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215410/ https://www.ncbi.nlm.nih.gov/pubmed/27690762 http://dx.doi.org/10.1080/21645515.2016.1219809

Ejemplares similares

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease
por: Benoit, Anne, et al.
Publicado: (2015)

Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness
por: Falsey, Ann R., et al.
Publicado: (2014)

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant
por: McAdams, David, et al.
Publicado: (2021)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
por: Langley, Joanne M., et al.
Publicado: (2017)

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age
por: Langley, Joanne, et al.
Publicado: (2020)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

Immunosenescence Modulation by Vaccination
por: McElhaney, Janet E.
Publicado: (2008)

Immunosenescence Modulation by Vaccination
por: McElhaney, Janet E.
Publicado: (2019)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
por: Oostvogels, Lidia, et al.
Publicado: (2019)

Combined Adjuvant Formulations Enhanced an Immune Response of Trivalent Foot and Mouth Disease Vaccine in Cattle
por: Ayele, Getu, et al.
Publicado: (2023)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
por: Waerlop, Gwenn, et al.
Publicado: (2023)

Vaccines for Improved Cellular Immunity to Influenza
por: Pawelec, Graham, et al.
Publicado: (2018)

Influence of Obesity on Pneumococcus Infection Risk in the Elderly
por: Frasca, Daniela, et al.
Publicado: (2019)

Recent advances in influenza vaccines
por: Pawelec, Graham, et al.
Publicado: (2020)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Improving seasonal influenza vaccination for older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

Postherpetic neuralgia in the elderly
por: Johnson, R W, et al.
Publicado: (2009)

Immunosenescence and Influenza Vaccine Efficacy
por: Sambhara, Suryaprakash, et al.
Publicado: (2009)

A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform
por: Kilgore, Paul B., et al.
Publicado: (2021)

Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
por: de Lusignan, Simon, et al.
Publicado: (2022)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™
por: Canelle, Quentin, et al.
Publicado: (2016)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: A double-blind randomized trial
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Age and frailty in COVID-19 vaccine development
por: Andrew, Melissa K, et al.
Publicado: (2021)

996. A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in US Nursing Homes
por: Gravenstein, Stefan, et al.
Publicado: (2018)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4b3pdlarlc65c3qsfekrfqq2jf